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http://www.rbej.com/content/12/1/2RESEARCH Open AccessLeucine-rich diet supplementation modulates
foetal muscle protein metabolism impaired by
Walker-256 tumour
Bread Cruz and Maria CC Gomes-Marcondes*Abstract
Background: Cancer-cachexia induces a variety of metabolic disorders of protein turnover and is more pronounced
when associated with pregnancy. Tumour-bearing pregnant rats have impaired protein balance, which decreases
protein synthesis and increases muscle breakdown. Because branched-chain amino acids, especially leucine,
stimulate protein synthesis, we investigated the effect of a leucine-rich diet on protein metabolism in the foetal
gastrocnemius muscles of tumour-bearing pregnant rats.
Methods: Foetuses of pregnant rats with or without Walker 256 tumours were divided into six groups. During
the 20 days of the experiment, the pregnant groups were fed with either a control diet (C, control rats; W,
tumour-bearing rats; Cp, rats pair-fed the same normoprotein-diet as the W group) or with a leucine-rich diet
(L, leucine rats; LW, leucine tumour-bearing rats; and Lp, rats pair-fed the same leucine-rich diet as the LW group).
After the mothers were sacrificed, the foetal gastrocnemius muscle samples were resected, and the protein
synthesis and degradation and tissue chymotrypsin-like, cathepsin and calpain enzyme activities were assayed. The
muscle oxidative enzymes (catalase, glutathione-S-transferase and superoxide dismutase), alkaline phosphatase
enzyme activities and lipid peroxidation (malondialdehyde) were also measured.
Results: Tumour growth led to a reduction in foetal weight associated with decreased serum protein, albumin and
glucose levels and low haematocrit in the foetuses of the W group, whereas in the LW foetuses, these changes
were less pronounced. Muscle protein synthesis (measured by L-[3H]-phenylalanine incorporation) was reduced
in the W foetuses but was restored in the LW group. Protein breakdown (as assessed by tyrosine release) was
enhanced in the L and W groups, but chymotrypsin-like activity increased only in group W and tended toward an
increase in the LW foetuses. The activity of cathepsin H was significantly higher in the W group foetuses, but the
proteolytic calcium-dependent pathway showed similar enzyme activity. In parallel, an intense oxidative stress
process was observed only in the group W foetuses.
Conclusions: These data suggested that the proteasomal and lysosomal proteolytic pathways and oxidative
stress are likely to participate in the process of foetal muscle catabolism of Walker’s tumour-bearing pregnant rats.
The present work shows that foetal muscle can be protected by supplementation with a leucine-rich diet.
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Pregnancy concomitant with cancer occurs in approxi-
mately one in one thousand women, but this combin-
ation is responsible for one-third of all maternal deaths
[1,2]. Relatively few relevant reports exist in the scientific
literature regarding the consequences of tumour growth
for the maternal host and the foetal body. Our previous
studies showed that tumour-bearing dam rats displayed
approximately 70% reabsorption and 50% foetal death
[3-6]; in this work, we focused on foetal growth be-
cause there is little data about the effects on foetal
homeostasis and damage when the mother suffers from a
tumour [7].
Tumour growth promotes extensive biochemical and
metabolic changes in the host organism, leading to the
process of cachexia and culminating in deep catabolism
of lean mass [8-10]. As a result, the host demonstrates
marked weight loss, which is not minimised by forced
feeding. To study these all these processes experi-
mentally, Walker-256 tumour is a good experimental
model of cachexia [9,10]. In addition, pregnancy causes
physiological changes that ensure foetal growth and
development until the term pregnancy and ensures an
adequate energy supply to the foetus and after birth
[11]. Additionally, during pregnancy, increased oxidative
stress can cause pre-eclampsia and intrauterine foetal
growth retardation [12], which may be promoted by
tumour development [13].
Branched-chain amino acids (BCAAs) are essential for
humans by promoting cell function and regulating
protein metabolism [14]. BCAAs, especially leucine
(Leu), have been studied because of their cell-signalling
properties; they can stimulate protein synthesis [14] and
decrease protein catabolism [6,14,15]. The oral adminis-
tration of exogenous leucine stimulates protein synthesis
in isolated or perfused rat muscles in vivo [16]. More-
over, clinical trials and studies in animals have shown
that supplementation with BCAAs increases the balance
of nitrogen and improves health after tissue damage,
such as that due to burns, radiation, post-surgical stress,
sepsis and cancer [17]. Studies have shown that the use
of complementary therapies, as nutritional supplemen-
tation, improves the clinical status and especially the
quality of life of cancer patients [18-21]. Meanwhile, ma-
ternal metabolism is directed to ensure the nutritional
supply for the foetus and adjust foetal growth, but the
combination of the metabolic and biochemical changes
during pregnancy and cancer jeopardises the foetus and
mother. Based on this, and more importantly because
there are few studies about the foetal consequences of
cancer development, this study investigated the effects
of Walker-tumour growth on protein catabolism in
foetal muscle, especially on proteolytic enzymes, anti-
oxidant enzymes and lipid peroxidation and examinedwhether nutritional supplementation with leucine modu-
lated the damage effects on foetal growth.Methods
Animals
We studied foetuses (20 days of gestational age) that
were obtained from pregnant adult Wistar rats. Female
Wistar rats (90 days old) were obtained from the Animal
Facilities Centre/UNICAMP and received food and water
ad libitum under controlled light–dark cycles (12/12 hours
each) at a constant temperature (22 + 2°C). The female
rats were bred with adult males (4:1 proportion) in collect-
ive cages for 12 hours [22]. After the first day of pregnancy
was determined by vaginal smears, the pregnant rats were
distributed into groups that either received or did not
receive a tumour implant and were either administered
nutritional supplementation or administered normal diet.
Walker carcinoma 256 tumour cells (2.5 × 105 viable cells
counted using the trypan blue method) were injected
subcutaneously on the 2nd day of pregnancy into the right
flank of the experimental rats. The pregnant rats in the
control groups received an equivalent volume of saline
solution (0.5 mL) in the subcutaneous tissue of their right
flanks. The handling of pregnant females with tumours
was previously described in protocol #657-1, which
was approved by the Ethics in Animal Experiments
(CEUA-IB-UNICAMP).Diet
The semi-purified, isocaloric diets were defined as either
normal (C - containing 18% protein [23]) or leucine-rich
(L - containing 18% protein plus 3% L-leucine, which
represents a high percentage of this amino acid). Both
diets contained 70% carbohydrates (sucrose, starch and
dextrin), 7% fat (soybean oil) and 5% fibre (micro-cellu-
lose purified). The diets were supplemented with a mix-
ture of vitamins, minerals, cysteine and choline. The
control diet contained 1.6% L-leucine, and the leucine-
rich diet contained 4.6% L-leucine; these diets were
identical to those used in our previous experimental
studies [5,24-26].Experimental protocol
The pregnant rats were distributed into 6 experimen-
tal groups according to tumour implant status and
nutritional supplementation. Pair-fed groups were cre-
ated to evaluate the effects of food intake reduction
observed in tumour-bearing groups [27,28]. At least
three foetuses per mother were collected to generate
a pooled sample (3 foetuses/dam) for each group. The
minimum number of mothers per group was at least
eight animals.
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 Rat foetuses (C) from pregnant rats subjected to a
normal diet.
 Rat foetuses (L) from pregnant rats subjected to a
leucine-rich diet.
 Rat foetuses (W) from Walker tumour-bearing
pregnant rats subjected to a normal diet.
 Rat foetuses (LW) from Walker tumour-bearing
pregnant rats subjected to a leucine-rich diet.
 Foetuses from pair-fed pregnant rats (Cp) subjected
to the normal diet and paired with group W.
 Foetuses from pair-fed pregnant rats (Lp) subjected
to a leucine-rich diet and paired with group LW.
The pregnant rats were maintained in collective cages
during the experimental period, except for the pair-fed
rats, which remained in metabolic cages and received
food intake in accordance with the tumour-bearing
groups, as previously determined in our lab studies [4].
After 20 days of pregnancy, the rats were sacrificed by
cervical dislocation, and the foetuses and placentas were
removed, dissected and weighed. The gastrocnemius
foetal muscles were dissected and weighed to assess
protein synthesis and degradation, and the activities of
oxidative stress enzymes and malondialdehyde were
assayed in foetal muscles. The foetal muscle homo-
genates were also analysed for the following enzyme
activities related to the protein degradation process: the
chymotrypsin-like enzyme of the ubiquitin-proteasome
pathway, the cathepsin enzyme of the lysosomal pathway
and the calpain enzyme of the calcium-dependent
pathway. We also evaluated the expression of the 20S
subunit of the ubiquitin-proteasome system.
Protein synthesis and degradation analyses
The synthesis and degradation of proteins was assessed
in pooled, foetal gastrocnemius muscles from each
mother. For statistical analysis, the number of pregnant
rats was at least 8 for the control groups and 10 to 12
for the tumour-bearing groups.
Protein synthesis assays were performed using
methods that were previously adapted in our laboratory
[6,28,29]. Pooled gastrocnemius muscles from both
posterior paws of the foetuses (at least 3 foetuses per
mother and were used at least 8 mothers per group)
were dissected, placed in tubes for perfusion with KHB
buffer (Krebs-Henseleit bicarbonate, 110 mM NaCl,
25 mM NaHCO3, 3.4 mM KCl, 1 mM CaCl2, 1 mM
MgSO4 and 1 mM KH2PO4; pH 7.4) supplemented with
5.5 mM glucose and 0.01% (w/v) albumin and incubated
at 37°C under continuous agitation in a 95% O2 and 5%
CO2 environment for 30 minutes. After this period,
fresh KHB buffer supplemented with 5 μCi of L[3H]-phenylalanine (Amersham, UK) and 60 mM cold phe-
nylalanine was added. After 2 hours of incubation, the
muscles were removed from the medium, dried, weighed,
frozen in liquid nitrogen and stored at −80°C. The muscles
were homogenised in 30% trichloroacetic acid (TCA) and
centrifuged at 11,000 × g for 15 min at 4°C. The resulting
pellet was washed twice with TCA (10%) to eliminate the
radioactivity of the supernatant. The pellet was treated
with 1 N NaOH and incubated at 40°C for 30 minutes.
The protein content of the aliquots was then analysed
[30], and the total β emission radioactivity was assessed
by liquid scintillation using beta-counting equipment
(Beckman LS 6000 TA, Fullerton, CA, USA). The rates
of protein synthesis, expressed as nanomoles of phenyl-
alanine incorporated per hour per milligram of muscle
protein, were calculated by dividing the amount of
radioactivity incorporated into the foetal muscle protein
over a 1-h period by the specific radioactivity of the
phenylalanine in the incubation medium.
A protein degradation assay was also adapted by our
laboratory [31] by measuring the amount of tyrosine that
was released into the muscle incubation solution. Each
pooled foetal gastrocnemius muscle sample (3 foetuses
per mother/group) was incubated for 30 min at 37°C in
RPMI 1640 medium. After this period, the muscles were
incubated in KHB solution containing cycloheximide
(a protein synthesis inhibitor) for 2 hours at 37°C in
a 5% CO2 and 95% O2 environment. After incubation,
the medium aliquots were treated with 30% TCA and
centrifuged at 4,500 × g for 10 min to assess the tyrosine
content using a fluorometric assay utilising 20% 1-nitroso-
2-naphthol reagent and nitric acid [32].
Biochemical assays to assess the muscle proteolytic
pathways and oxidative stress
The foetal gastrocnemius muscle samples were homo-
genised in homogenising buffer (20 mM Tris, 1 mM
DTT, 2 mM ATP and 5 mM MgCl2), resolved on
12% acrylamide-SDS gels and transferred to nitrocellulose
membranes. A primary monoclonal antibody against the
20S subunit of the proteasome (Affinity, England) (1:1,000
dilution) was used, and a secondary goat anti-mouse
antibody was used to react with the primary antibody
(Santa Cruz, USA) (1:1,000). The chemiluminescence
reaction was performed using ECL reagents (Amersham),
and the quantification of protein-band density was carried
out using Image Capture (Amersham) and Gel Pro II-Plus
software (Silver Spring, MD, USA).
The foetal muscle homogenates was also analysed for
total protein content [30] and for chymotrypsin-like, ca-
thepsin and calpain enzyme activity. Chymotrypsin-like
activity, which is the proteolytic activity of the ubiquitin-
proteasome pathway, was evaluated using the substrate
N-Succinyl-Leu-Leu-Val-Tyr-7-Amino-4-Methylcoumarin
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(pH 8.0) and assessed using the fluorometric method at
360 nm excitation and 460 nm emission [33]. The activity
of cathepsin, which is a lysosomal proteinase, was
evaluated using a fluorometric method and the substrate
benzyloxycarbonyl-phenylalanine- arginine 4-methyl-7-
coumarilamide at 340 nm excitation and 460 nm emission
[34]. Calpain, which is a proteinase involved in calcium-
dependent protein degradation, was measured by incu-
bating the samples in reaction buffer with casein for 5
minutes followed by the addition of 5 mM CaCl2 and
subsequently reading the absorbance at 500 nm in a
spectrophotometer according to the previously described
colourimetric methodology [34].
Aliquots of the muscle-homogenate supernatant were
analysed for glutathione-S-transferase (GST) activity
based on the conjugation of 1-chloro-2,4-dinitrobenzene
(CDNB; Sigma) with glutathione, and the activity was
expressed as nmol·μg protein-1·min-1 using an extinction
coefficient of 9.6 as previously described [35]. The
catalase activity was measured as described by Cohen
[36], and the results are expressed as nmol/min/mg
protein. Alkaline phosphatase activity was measured using
37 mM 4-nitrophenyl disodium phosphate (p- NPP) and
expressed in nmol/min/mg protein [37]. The amount of
the lipid peroxidation product, malondialdehyde (MDA),
was determined by incubating the samples with MPO
(n-methyl-2-phenylindole; Sigma) and measuring the
absorbance at 590 nm; the results are expressed as
nmol·μg protein-1 [38].
After decapitation, foetal blood was collected using a
microcapillary tube and then centrifuged to assay the
haematocrit and obtain the foetal serum. The total protein
concentration in the foetal serum was determined using
the Biuret test, which is a colourimetric reaction that was
read at 540 nm [39]. The albumin concentration in the
foetal serum was determined using colourimetric method-
ology by reading a bromocresol green reaction at 630 nm
[40]. The glucose level was quantified using an enzymatic
reaction based on glucose-oxidase [41].
Statistical analysis
The results are reported as the means and standard
error. The data were analysed using two-way ANOVA
tests to detect the effects of diet, tumours, and the
pair-feeding scheme on the foetal parameters (weight,
enzyme activities and protein synthesis and degradation).
The comparisons within the control and tumour-
bearing groups were performed using one-way ANOVA
followed by Bonferroni multiple-comparison tests
[42]. The calculations were performed using Graph-
Pad Prism 3.0 software (GraphPad Inc., San Diego,
CA, USA), and values of P < 0.05 indicate statistical
significance.Results
In the present study, the foetuses of tumour-bearing
pregnant rats suffered similar effects due to tumour
growth as those observed in tumour-bearing animals
[5,6,15,25,27]. The weight of the foetuses in the W and
LW groups was reduced (Figure 1A), and in this case
the tumour effects account for 83% of the total variation,
indicating that this low foetal weight is extremely signifi-
cant. Consistent with this reduced foetal weight, the
ratio of the foetal weight to the placental weight, which
is indicative of the efficiency of placental transport, was
decreased in both tumour-bearing groups and in the
leucine pair-fed foetuses, especially when compared to
the control rats (Figure 1B). These data show that the
tumours and the pair-feeding scheme accounted for this
impaired effect (P < 0.0002). The reduction in foetal
weight occurred in parallel with the group with the
lowest concentration of total foetal serum protein, group
W, which was 27% lower than that of the control group,
C (Figure 1C). In contrast, the total foetal serum protein
of the LW group was similar to that of the control group
(C) and higher than that of the W group (P = 0.0029).
The serum albumin levels of the rats in the tumour-
bearing group (W) were reduced by approximately 31%
compared to those in group LW (P < 0.0001), which had
a similar value to that of the control group (Figure 1D).
Although the albumin-serum content was 20% higher in
group L (under nutritional supplementation) than in
group C, the leucine-rich diet did not prevent the
reduction in albumin levels in the foetuses from
tumour-bearing rats, as observed when comparing the
LW and L groups (Figure 1D, P < 0.0001). Similarly, we
observed a reduction in glucose levels in tumour-bearing
foetuses, and those in the W groups showed a severe
decrease in glucose levels (Figure 1E). Furthermore,
the haematocrit was reduced only in the W group
(Figure 1F). These data show that diet accounted for
46.7% of the total variance (P < 0.0001), modulating
the effect of Walker tumour development.
Tumour growth affected anti-oxidative enzyme activ-
ities and increased lipid peroxidation (malondialdehyde)
in foetal gastrocnemius muscles (Figure 2). Alkaline
phosphatase activity could be used to test muscle-cell
function [37], which was decreased in the W foetuses,
but leucine supplementation led to a similar level in the
LW group. In contrast, the L, Cp and Lp groups
displayed increases in alkaline phosphatase activity
compared to the control or tumour-bearing groups
(Figure 2A). In comparison to the C group, glutathione-
S-transferase activity was reduced in the W group but
was similar in the LW group and increased in the L, Cp
and Lp groups (Figure 2B). Catalase activity increased
significantly only in the W group (Figure 2C), and gluta-
thione levels tended to increase only in the W group
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Figure 1 Foetal tissues. Foetal weight (A), the foetal/placental weight ratio (B), total serum protein (C), albumin (D) and glucose (E) levels and
haematocrit (F) of foetuses from Walker 256 carcinoma-bearing pregnant rats that were administered a leucine-rich or control diet. Legend:
C – control rats; L – rats fed a leucine-rich diet; W – tumour-bearing rats; LW – tumour-bearing rats fed a leucine-rich diet; Cp – rats subjected to
a similar, paired-nutrition intake of rats in group W; and Lp – rats subjected to a leucine-rich diet and nutrition that was paired to the intake of
rats in Group LW. * P < 0.05, significantly different compared to group C. • P < 0.05, significantly different compared to group L. a P < 0.05,
significantly different compared to groups W and LW. # P < 0.05, significantly different from group W.
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pressed by the malondialdehyde level, increased only in
the W group (Figure 2E), and the MDA/GST ratio was
increased 3-fold in the W group compared to the LWgroup (Figure 2F). These data show that diet accounted
for 27% of the total variance in enzyme activity, modu-
lating the tumour changes to foetal antioxidant enzyme
activities.
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Figure 2 Foetal muscles. Alkaline phosphatase (A), glutathione-S-transferase (B), catalase (C), glutathione (D), malondialdehyde (E) levels and
the MDA/GST ratio (F) of the foetal muscle from Walker 256 carcinoma-bearing pregnant rats that were subjected to a leucine-rich or control diet.
Legend: C – control rats; L – rats fed a leucine-rich diet; W – tumour-bearing rats; LW – tumour-bearing rats fed a leucine-rich diet; Cp – rats
subjected to a similar, paired-nutrition intake of rats in group W; and Lp – rats subjected to leucine-rich diet and nutrition that was paired to
the intake of rats in Group LW. * P < 0.05, significantly different compared to group C. • P < 0.05, significantly different compared to group L.
aP < 0.05; significantly different compared to groups W and LW. # P < 0.05, significantly different from group W.
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decreased in both of the Walker tumour-bearing groups
(W and LW) compared to the control groups (C and L).
Despite the food restriction that was imposed by pair
feeding, no differences in the foetal muscle protein con-
tent in the pair-fed groups (Cp and Lp) were observed.
Foetal muscle protein synthesis, as determined by the in-
corporation of phenylalanine (L-[3H]-Phe), was approxi-
mately 27% lower in the foetuses of tumour-bearing
pregnant rats (W) than in the LW group (P = 0.0103)
and other groups (Figure 3B). As a result of leucine sup-
plementation, muscle protein synthesis recovered in the
LW group, and this change was significantly differentfrom that of the W group; diet significantly modulated
the tumour effect (P = 0.0005). In addition, the mal-
nutrition factor that was imposed by food restriction,
measured in the pair-fed groups (Cp and Lp), had no
effect on the protein synthesis process (Figure 3B).
Foetal muscle protein degradation was evaluated by
the amount of released tyrosine and was approximately
31% higher in the W group than in the control group C
(Figure 3C); in this case, the diet also accounted for a
significant modulation of tumour effect (P = 0.0038).
The chymotrypsin-like enzymatic activity, which is the
catalytic portion of the ubiquitin-proteasome, was in-
creased approximately 3.9-fold in group W, and despite
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Figure 3 Foetal muscle protein synthesis and degradation. Total
foetal muscle protein (μg · mg-1) (A), muscle protein synthesis
(nmol · μg protein-1 · h-1) (B) and muscle protein degradation
(nmol · μg protein-1 · h-1) (C) in foetuses of tumour-bearing pregnant
rats that were subjected to a leucine-rich or control diet. Protein
synthesis was assessed by measuring phenylalanine incorporation
(for details, see Methods), and protein degradation was assessed by
the amount of tyrosine that was released from perfused muscle
(for details, see Methods). Legend: C – control rats; L – rats fed a
leucine-rich diet; W – tumour-bearing rats; LW – tumour-bearing
rats fed a leucine-rich diet; Cp – rats subjected to a similar, paired-
nutrition intake of rats in Group W; and Lp – rats subjected to a
leucine-rich diet and nutrition that was paired to the intake of the
rats in Group LW. * P < 0.05; significantly different compared to
group C. • P < 0.05; significantly different compared to group L.
aP < 0.05; significantly different compared to groups W or LW.
# P < 0.05, significantly different from group W.
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received a leucine-rich diet (LW) showed a less-pro-
nounced increase in the chymotrypsin-like activity
compared to the rats in group W. These differences
were near statistical significance (Figure 4A; P = 0.0803).
The pair-fed groups (Cp and Lp) showed an increase in
chymotrypsin-like enzyme activity that was similar to
that observed in the LW group when compared to the L
group. Furthermore, the expression of the 20S subunit
of the ubiquitin-proteasome was decreased in the
tumour-bearing groups (W and LW) and the pair-fed
groups (Cp and Lp) (Figure 4B). Cathepsin H, which is
one of the enzymes involved in the lysosomal proteolytic
pathway, showed significantly increased activity in the
W group, but this increase was less pronounced in the
LW group (Figure 4C) (P < 0.047); in this case, the diet
modulated the effect of tumour growth. The calcium-
dependent proteolytic pathway showed no difference in
its calpain activity between the tumour-bearing groups
when compared to the C group, but the L and Lp groups
showed decreased activity in relation to the values
observed in group C rats (Figure 4D).
Discussion
Maternal physiological adaptations are impaired by can-
cer development and can lead to impaired foetal growth
and development. Here, we clearly show that in the
presence of Walker-256 tumour growth, foetal develop-
ment was jeopardised, especially with respect to muscle
protein metabolism linked to increased proteolysis and
inhibited protein synthesis. These effects were likely
associated with the lack of an anti-oxidative response,
which reduced foetal weight. More importantly, we
observed that nutritional supplementation with leucine
led to a marked modulatory effect that minimised foetal
proteolysis, maintained the balance of similar levels of
protein synthesis and degradation, and restored the anti-
oxidant responses.
Previous studies found that the presence of a tumour
affected foetal weight [4,5]. This decrease in foetal
weight was related to a reduction in placental weight,
which may be related to changes in placental tissue, and
decreased the foetal/placental weight ratio (Figure 1),
leading to impaired foetal development. Foetal growth in
rats is more intense during the third phase of pregnancy
(19th - 21st day), which coincides with the greatest
tumour weight [3,5]. The high activity of tumour cells
that promotes exponential growth occurs during the
same period of foetal growth. Thus, we verified that, at
the time points when the tumour weighed approximately
10 to 12% of the maternal body weight, the W foetuses
also displayed reductions in body weight, total serum
protein, albumin and glucose that was coupled with a
decline in muscle protein synthesis and increased
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Figure 4 Foetal muscle enzymes related to protein degradation. Muscle chymotrypsin enzyme activity (A), the 20S proteasome subunit (B),
cathepsin H enzyme activity (C), and calpain activity (D) in foetal muscle from tumour-bearing pregnant rats that were subjected to a leucine-rich
or control diet. Representative image showing the expression of the 20S proteasome subunit from each different animal per group; the 20S
expression was corrected for actin expression, which was used as a loading control (data not shown) (for details, see Methods). The minimum
number of animals used per group was 8. Legend: C – control rats; L – rats fed a leucine-rich diet; W – tumour-bearing rats; LW - tumour-bearing
rats fed a leucine-rich diet; Cp – rats subjected to a paired-nutrition intake identical to the rats in Group W; and Lp – rats subjected to a leucine-rich
diet whose nutrition was paired to the intake of the rats in Group LW. * P < 0.05; significantly different compared to group C. • P < 0.05; significantly
different compared to group L. a P < 0.05; significantly different from groups W and LW. # P < 0.05, significantly different from group W.
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bolic changes that occur during tumourigenesis [25], as
was found in the group W foetuses. Proteolysis is the
main process during cancer-cachexia, and this can be
assessed by a decrease in albumin content, followed by
the catabolism of skeletal muscle cells, promoting atro-
phy and apoptosis [43,44]. Although the total muscle
protein decreased in both of the tumour-bearing groups
(W and LW), a leucine-rich diet maintained protein syn-
thesis and reduced protein degradation in the LW group.
This observation suggests that the LW group had a less
intense catabolism of lean body mass, as was verified in
the W group, which was likely related to the degradation
of foetal muscle protein that was enhanced by oxidative
stress [38,45]. According to our previous studies, lean
body mass was reduced during tumour growth, and
dietary supplementation with leucine minimised this loss
[3,5,8,24]. Intense protein catabolism, primarily in the
skeletal muscle, may have provided substrates, pre-
dominantly amino acids and gluconeogenic substrates,to be used by neoplastic cells [25,46,47]. Consequently,
it is thought that tumour development induces a devi-
ation of nutrients from the placenta and foetus (which is
the reason for the decrease in foetal weight and reduc-
tion in the foetus/placenta ratio that is associated with
increased protein degradation and oxidative stress). In
parallel, the foetuses from mothers that were subjected
to graduated food restriction (Cp and Lp) showed re-
duced weight, but their serum parameters and total
muscle protein were similar to those of the control
group animals. Nutritional supplements are particularly
important for foetal viability and foetus/placenta unity,
but foetuses have the capacity to adapt metabolically to
acute and chronic changes in maternal and foetal serum
nutrients content [48,49]. In contrast, we show that
foetuses from tumour-bearing mothers, primarily those
in group W, were not able to efficiently adapt their
metabolism under cancer conditions compared to those
under food restriction, as found in pair-fed foetuses
(Cp). This fact may be related to the action of substances
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reported [4,7,50,51]. Carbo and colleagues [52] found
deficits in the amino acid mobilisation of foetuses in
pregnant rats that received tumour necrosis factor dur-
ing pregnancy, and this was associated with decreased
placental blood flow due to the action of this cytokine.
We previously verified that pregnant rats that were
injected with ascitic liquid (obtained from tumour-
bearing animals without tumour cells) exhibited an
increase in foetal reabsorption and a reduction in foetal
and placental weight; similar deleterious effects were
found in tumour-bearing mothers [3,4,50]. In these ex-
periments, we proposed that these changes were induced
by substances produced by cancer cells and did not
result from only the effect of reducing nutrients, as was
observed in this study when comparing the W and Cp
foetuses.
Pregnancy changes, especially the increase in muscle
protein breakdown, are related to the effects of the
tumour on the body. In the cancer host, the catabolism
that is associated with the reduction and/or maintenance
of the protein synthesis process is increased [24,53] and
is related to increased oxidative stress [38,45,50]. In this
case, the foetuses from the rats in group W displayed
reduced protein synthesis, which was also associated
with an increase in proteolysis caused by the activation of
proteolytic systems and a high oxidative stress process.
The ubiquitin-proteasome pathway can be modulated by a
leucine-rich diet [6,8]. As has been reported in many other
studies, the activity of this process was higher and more
widely observed in foetal cells. The 20S subunit, which
comprises the catalytic core of the ubiquitin-proteasome
proteolytic pathway, is most likely involved in protein
turnover, leading to differentiation and development of
embryonic and foetal tissues. However, we showed that
although the 20S subunit was expressed at lower levels in
the W and LW foetuses, the greater chymotrypsin-like
activity and oxidative stress that were found in group W
were sufficient to promote protein wasting in those
foetuses. More importantly, under leucine nutritional
supplementation, the LW foetuses showed less increased
protein degradation because leucine diminished the
increase in chymotrypsin activity and maintained the
cathepsin enzyme while increasing the antioxidant re-
sponse; these results suggest a beneficial effect of leucine
in minimising proteolysis. Moreover, tumour growth
produces alterations that affect placental metabolism and
interact with the placenta-foetus, as evidenced by intra-
uterine growth restriction with increased foetal-muscle
catabolism [3,4,6,24,52].
Nutritional supplementation with leucine provides
several benefits by activating cellular synthesis processes
[6,24,25]. These data suggest that the foetuses that
received nutritional leucine supplementation, even thosethat were suffering from their mother’s tumours, showed
diminished deleterious effects due to tumour growth
compared to those that did not receive leucine; the
foetuses in the LW group had similar muscle protein
synthesis to the control foetuses, and more importantly,
the process of protein catabolism was minimised and
was equal to that of the control group [4,5,54]. Further
studies are underway in our laboratory to determine
whether leucine supplementation can counteract the
damage to foetal growth during cancer development and
the mechanism underlying this effect. These data indi-
cate the importance of co-adjuvant therapy in improving
the state of host responses to clinical treatment and par-
ticularly the importance of leucine supplementation,
which has a positive effect on the host mother and on
foetal development.
Conclusions
The nutritional supplementation of a leucine-rich diet
induced protein synthesis in the skeletal muscle of
foetuses of pregnant, tumour-bearing rats. This effect
may be due to minimisation of protein catabolism and
enhancement of the anti-oxidative response.
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